| Hint | Answer | % Correct |
|---|---|---|
| IL-1 antagonist for RA | anakinra | 67%
|
| DMARD inhibitor of calcineurin for RA, UC and organ rejection | cyclosporin | 67%
|
| Fusion protein of 2 soluble TNFaRs | etanercept | 67%
|
| Block receptor to prevent aldosterone release, AT1R antagonists | losartan | 67%
|
| DMARD - dihydrofolate reductase inhibitor to inhibit thymine | methotrexate | 67%
|
| B-adrenoceptor antagonists to slow heart rate, anti-arrhythmic | propanolol | 67%
|
| HMG CoA reductase inhibition, increase LDLR expression | statins | 67%
|
| JAK inhibitor for RA | tofacitinib | 67%
|
| TNFa inhibitor | adalimumab | 33%
|
| Inhibitor of PCSK9 | alirocumab | 33%
|
| DMARD inhibiting purine synthesis | azathioprine | 33%
|
| Reduce aldosterone production, reduce blood pressure, ACEIs | captopril | 33%
|
| Loop diuretic specific for pulmonary oedema, prevents salt/water retention | furosemide | 33%
|
| P2X3 inhibitor on sensory nerves for cough | gefapixant | 33%
|
| siRNA to inhibit IC synthesis of PCSK9 | inclisiran | 33%
|
| TNFa inhibitor | infliximab | 33%
|
| CFTR channel potentiator | ivacaftor | 33%
|
| Chaperone for CFTR folding, increases CFTR at membrane | lumacaftor | 33%
|
| What previous is converted into to inhibit amidophosphoribosyltransferase | mercaptopurine | 33%
|
| DMARD increasing PPARy activation for RA and UC | mesalazine | 33%
|
| Bound IL-6R inhibitor preventing gp130 binding | olamkicept | 33%
|
| IL-6 inhibitor to prevent gp130 binding for RA and covid | olokizumab | 33%
|
| siRNA to interfere with production of apolipoprotein a | olpasiran | 33%
|
| PDE4 selective inhibitor | roflumilast | 33%
|
| IL-6 inhibitor for RA | sirukumab | 33%
|
| CFTR protein folding corrector | tezacaftor | 33%
|
| IL-6R inhibitor for RA | tocilizumab | 33%
|
| Stimulates GC in absence of NO increasing renal blood flow, vasodilation | vericiguat | 33%
|
| IL-5R inhibitor, preventing IL-5 activation of baso/eosinophils | benralizumab | 0%
|
| SGLT2 inhibitors preventing glucose reabsorption in kidneys, no hr effect | dapagliflozin | 0%
|
| Anti-oxidant, aiding in protection from free radicals | edaravone | 0%
|
| PDE3 selective inhibitor | enoximone | 0%
|
| Non-selective inhibitor of both PDE3 and 4 | ensifentrine | 0%
|
| Blocks presynaptic Na+ channels to prevent glutamate transmission | riluzole | 0%
|
| Anti-CD20 antibodies for MS and RA | rituximab | 0%
|
| Neprilysin inhibitor | sacubitril | 0%
|
| Aldosterone receptor antagonist reversing left ventricular hypertrophy | spironolactone | 0%
|
| TSLP (alarmin) inhibitor to reduce expression with allergen presence | tezepelumab | 0%
|